# Dopamine Enhancement of Fear Extinction Learning in PTSD (1R21MH108753)

> **NCT02560389** · PHASE4 · COMPLETED · sponsor: **University of Wisconsin, Madison** · enrollment: 103 (actual)

## Conditions studied

- Stress Disorder, Post Traumatic

## Interventions

- **DRUG:** Placebo
- **DRUG:** Levodopa

## Key facts

- **NCT ID:** NCT02560389
- **Lead sponsor:** University of Wisconsin, Madison
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03
- **Primary completion:** 2018-05-01
- **Final completion:** 2018-05-01
- **Target enrollment:** 103 (ACTUAL)
- **Last updated:** 2019-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02560389

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02560389, "Dopamine Enhancement of Fear Extinction Learning in PTSD (1R21MH108753)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02560389. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*